Skip to main content
Ileana Soto Mauldin, PhD

Ileana Soto Mauldin, PhD

Research Assistant Professor of Surgery, Surgery

Primary Phone Number

Bio & Overview

Academic Information

Department
Surgery

Primary Education

  • B.S., Applied Biology, Georgia Technull
  • M.S., Biological and Physical Sciences, University of Virginianull
  • Ph.D., Microbiology and Immunology, University of Virginianull

Research Interests

Pathology

Research Disciplines

  • Cancer Biology
  • Experimental Pathology
  • Immunology
  • Microbiology

Research Opportunities

  • Cancer Biology
  • Cancer Immunology and Immunotherapy
  • Experimental Pathology
  • Immunology
  • Microbiology

PhD Programs

  • Experimental Pathology

Selected Publications

2026

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Cancer Medicine. 2026; 15(1):. DOI:10.1002/CAM4.71526.

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
Journal for ImmunoTherapy of Cancer. 2026; 14(3): e013613. DOI:10.1136/JITC-2025-013613.

2025

Abstract 3474: Breast cancer control and increased TIL with intratumoral TLR2 agonist and IFNγ
Cancer Research. 2025; 85(8_Supplement_1): 3474 - 3474. DOI:10.1158/1538-7445.AM2025-3474.

Editorial: Tumor-associated tertiary lymphoid structures response during immunotherapy
Frontiers in Immunology. 2025; 16:. DOI:10.3389/FIMMU.2025.1591820.

2024

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer. 2024; 12(9): e009126. DOI:10.1136/JITC-2024-009126.

2023

In silico optimization of prenatal vaccine regimens to promote early-life immunity
Journal of immunology. 2023; 210(Supplement_1): 252.20 - 252.20. DOI:10.4049/JIMMUNOL.210.SUPP.252.20.

Systems approaches to characterize the local heterogeneities in NK cell antitumor immunity in MHC I-disparate human non-small cell lung cancer
Journal of immunology. 2023; 210(Supplement_1): 62.08 - 62.08. DOI:10.4049/JIMMUNOL.210.SUPP.62.08.

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas
OncoImmunology. 2023; 12(1):. DOI:10.1080/2162402X.2022.2164476.

2022

CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab
Melanoma Research. 2022; 32(6): 440 - 450. DOI:10.1097/CMR.0000000000000855.

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
Journal for ImmunoTherapy of Cancer. 2022; 10(9): e005424. DOI:10.1136/JITC-2022-005424.

2021

337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab
Journal for ImmunoTherapy of Cancer. 2021; A363 - A363. DOI:10.1136/JITC-2021-SITC2021.337.

388 A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies)
Journal for ImmunoTherapy of Cancer. 2021; A421 - A421. DOI:10.1136/JITC-2021-SITC2021.388.

47 Tertiary lymphoid structures (TLS) in desmoplastic melanomas (DM) differ from non-DM-associated TLS by their intratumoral location and enhanced immune activity
Journal for ImmunoTherapy of Cancer. 2021; A54 - A54. DOI:10.1136/JITC-2021-SITC2021.047.

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
OncoImmunology. 2021; 10(1):. DOI:10.1080/2162402X.2021.1898105.

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma
Journal for ImmunoTherapy of Cancer. 2021; 9(6): e002273. DOI:10.1136/JITC-2020-002273.

Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
Cell Reports. 2021; 36(3): 109422. DOI:10.1016/J.CELREP.2021.109422.

Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma
Cells. 2021; 10(12): 3378. DOI:10.3390/CELLS10123378.

2020

Characteristics of Tertiary Lymphoid Structures in Melanoma Skin Metastases Predict Overall Survival
Journal of the American College of Surgeons. 2020; 231(4): S264. DOI:10.1016/J.JAMCOLLSURG.2020.07.578.

Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts
SSRN Electronic Journal. 2020; DOI:10.2139/SSRN.3575119.

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
Journal for ImmunoTherapy of Cancer. 2020; 8(1): e000544. DOI:10.1136/JITC-2020-000544.

2019

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors
Cancer Immunology, Immunotherapy. 2019; 68(7): 1121 - 1132. DOI:10.1007/S00262-019-02345-5.

2018

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma
OncoImmunology. 2018; 7(10): e1490855. DOI:10.1080/2162402X.2018.1490855.

IMMU-69. PROGNOSTIC IMPLICATION OF B-CELL INFILTRATE IN PATIENTS WITH GLIOBLASTOMA (GBM)
Neuro-Oncology. 2018; 20(suppl_6): vi137 - vi137. DOI:10.1093/NEUONC/NOY148.572.

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Journal of immunology. 2018; 200(2): 432 - 442. DOI:10.4049/JIMMUNOL.1701269.

Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures
Melanoma Research. 2018; 28(3): 237 - 245. DOI:10.1097/CMR.0000000000000439.

Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
Journal of Clinical Oncology. 2018; 36(15_suppl): 3033 - 3033. DOI:10.1200/JCO.2018.36.15_SUPPL.3033.

2017

Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells
Frontiers in Physiology. 2017; 8:. DOI:10.3389/FPHYS.2017.00719.

2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016
Journal for ImmunoTherapy of Cancer. 2016; 4(S1):. DOI:10.1186/S40425-016-0173-6.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites
Cancer Immunology, Immunotherapy. 2016; 65(1): 25 - 36. DOI:10.1007/S00262-015-1770-9.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk
OncoImmunology. 2016; 5(12): e1240857. DOI:10.1080/2162402X.2016.1240857.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Cancer Immunology, Immunotherapy. 2016; 65(10): 1189 - 1199. DOI:10.1007/S00262-016-1881-Y.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Cancer Immunology, Immunotherapy. 2016; 65(10): 1201 - 1212. DOI:10.1007/S00262-016-1880-Z.